Now Reading:
Sirnaomics Publishes Research on Cancer Drug Candidate
Full Article 40 second read

Sirnaomics Publishes Research on Cancer Drug Candidate

By Karen E. Roman

Sirnaomics Ltd., a biopharmaceutical company developing RNAi therapeutics, recently published a research article showing a cancer drug candidate to treat solid tumors.

The article focused on the company’s clinical studies with STP707, a polypeptide nanoparticle  formulation, and provided a foundation for further research to treat hepatocellular carcinoma and other solid tumors, the company said.

“The newly described mechanism of action provides further scientific foundation for recent successes from our Phase I clinical study for STP707, as a single drug and, potentially, in combination with immune checkpoint inhibitors,” said Dr. Patrick Lu, Sirnaomics’ Chief Executive Officer.



Healthcare Edge



Leave a Reply

Your email address will not be published. Required fields are marked *

Input your search keywords and press Enter.